Superbug Infection After Endoscopy Lawsuit — Legal Rights for Patients Who Developed Antibiotic-Resistant Infections

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Olympus Scope — Infection Claims

Hospitalized With an Infection After a Scope Procedure?

If you were told it was “just a complication,” Olympus’s federal guilty plea — and $85 million in penalties — tell a different story. In two minutes, you can know whether your case qualifies.

ACTIVE LITIGATION. 250+ patients · most recent filing: June 2026 · deadlines vary by state — some as short as one year.

Were you hospitalized with an infection within 30 days of an endoscopy or scope procedure?

Yes — See If My Case Qualifiesfree · takes 2 minutes
I think so / not sure

Free · confidential · no fee unless there is a recovery · answering doesn’t commit you to anything. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Prefer to talk it through? (888) 348-2735 — free and confidential.

Stefanie A. Murphy & Matthew T. Marin

Partners

You’ll get a straight answer even if it’s “you don’t qualify.” Everything you share is confidential — even if you never hire us. No fee unless there is a recovery; costs are advanced and reimbursed only out of a recovery. If you do qualify, our Olympus scope litigation team requests the medical and hospital records — you don’t chase them.

Qualification depends on what the medical records show — the scope involved, the infection, and the timing. We’ll review them and give you a straight answer either way.

Contaminated Olympus endoscopes have been linked to antibiotic-resistant superbug infections at hospitals across the United States. Patients who developed an antibiotic-resistant infection — including CRE, NDM-1, MRSA, VRE, ESBL, Klebsiella pneumoniae, or Pseudomonas aeruginosa — after a scope procedure performed on or after January 1, 2015, and who required inpatient hospitalization and IV antibiotic treatment within 30 days of that procedure, may have a product liability claim against Olympus Corporation, the device manufacturer.

What Is a Superbug Infection and How Are Endoscopes Linked?

A superbug is a bacterium that has evolved resistance to multiple antibiotics, including last-resort drugs such as carbapenems and vancomycin. When a superbug enters the bloodstream, standard treatments fail. Carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infections carry a mortality rate approaching 50% (Source: CDC MMWR Vital Signs, March 5, 2013). These organisms do not respond to the antibiotics clinicians rely on most heavily, forcing physicians to use treatments that are more toxic, less effective, or both.Endoscopes are uniquely dangerous vehicles for superbug transmission. These complex, flexible instruments contain hollow internal channels, biopsy ports, and elevator mechanisms that cannot be heat-sterilized — only chemically disinfected. Bacteria survive in these channels even after staff follow the manufacturer’s recommended reprocessing protocols exactly. Three independent research groups have confirmed this contamination problem across three different methodologies and time periods:Standard high-level disinfection leaves approximately 15% of patient-ready duodenoscopes contaminated with bacteria — frequently gut organisms — even when hospital staff follow the manufacturer’s reprocessing instructions (Source: Larsen S, et al., EClinicalMedicine. 2020;25:100451. PMID: 32954234.). A 2022 meta-analysis of 9,084 post-reprocessing cultures found 5% contamination even after enhanced cleaning protocols, with 0.8% involving high-risk organisms (Source: Bomman et al., Clinical Endoscopy, January 2022, PMC8831410). Most strikingly, an 8-year retrospective study at a Dutch tertiary-care hospital found that by 2022, 94.7% of patient-ready scopes showed measurable bacterial contamination of any type (AM20 — any-organism contamination, not patient-origin bacteria specifically), with the patient-origin bacteria (MGO) contamination rate ranging from 14.3% to 47.5% annually — and all manufacturer-recommended interventions failed to produce a meaningful reduction in contamination rates over the entire study period (Source: van der Ploeg et al., Gut, March 2024, PMID 38182137, DOI: 10.1136/gutjnl-2023-330355).The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee documented at least 250 patients worldwide who contracted potentially deadly infections from contaminated duodenoscopes, and stated that figure is likely a significant undercount (Source: Senate HELP Committee, “Preventable Tragedies: Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients,” January 13, 2016). The report’s very title — “Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients” — signals the direct connection between Olympus scope design failures and the superbug crisis in U.S. hospitals.

Which Superbugs Have Been Linked to Contaminated Olympus Scopes?

CRE (Carbapenem-Resistant Enterobacteriaceae): CRE is the primary superbug documented across every major Olympus scope outbreak in the United States. CRE bacteria are resistant to carbapenem antibiotics — the last line of defense for serious gram-negative infections — and carry a bloodstream mortality rate approaching 50% (Source: CDC MMWR, March 5, 2013). CRE caused the documented outbreaks at Virginia Mason Medical Center in Seattle, Ronald Reagan UCLA Medical Center, and the hospitals named in the Senate HELP Committee investigation.NDM-1 (New Delhi Metallo-Beta-Lactamase): NDM-1 is a specific enzyme that confers resistance to nearly all antibiotics, leaving physicians with almost no effective treatment options. ESBL (Extended-Spectrum Beta-Lactamase): ESBL-producing bacteria are resistant to penicillins and cephalosporins, two of the most widely used antibiotic classes. ESBL organisms have been documented in multiple healthcare-associated infection outbreaks linked to contaminated endoscopic equipment and represent an increasingly common contamination threat in scope procedures.VRE (Vancomycin-Resistant Enterococcus): VRE is resistant to vancomycin, a key antibiotic for treating serious gram-positive infections. VRE infections acquired during endoscopy are recognized as healthcare-associated infections by the CDC and have been documented in facilities using contaminated scope equipment.MRSA (Methicillin-Resistant Staphylococcus aureus): MRSA is resistant to methicillin and related beta-lactam antibiotics and is a well-established cause of difficult-to-treat hospital-acquired infections. MRSA transmission through contaminated endoscopes has been documented in published medical literature and in FDA adverse event reports.Klebsiella pneumoniae and Pseudomonas aeruginosa: Klebsiella pneumoniae — including the OXA-232 carbapenem-resistant strain — was the primary pathogen in the documented outbreak at Ronald Reagan UCLA Medical Center, infecting 17 patients including 9 confirmed active infections, 7 asymptomatic carriers, and 1 index patient (Source: Humphries et al., Clinical Infectious Diseases, 2017, PMID 29579235). Pseudomonas aeruginosa is an opportunistic pathogen that has been recovered from contaminated endoscope channels and is associated with serious respiratory and bloodstream infections in immunocompromised patients.

Which Hospital Outbreaks Have Been Linked to Olympus Scope Superbugs?

Virginia Mason Medical Center (Seattle, WA): Between November 2012 and August 2013, Virginia Mason experienced an outbreak of MDR (multidrug-resistant) E. coli traced to contaminated Olympus duodenoscopes. Of 1,149 ERCP procedures performed during this period, 32 patients were infected. Seven patients died within 30 days of the positive culture; 16 patients had died by March 2015; and 18 total outbreak-associated deaths were ultimately documented. MDR E. coli was recovered from 4 of 8 Olympus duodenoscopes tested — despite no identified breach in the hospital’s high-level disinfection protocol. The peer-reviewed paper stated: “The existing manufacturer-recommended high-level disinfection protocols for duodenoscopes are inadequate” (Source: Ross et al., Gastrointestinal Endoscopy, September 2015, Vol. 82(3):477–83, PMID 26092616).Ronald Reagan UCLA Medical Center (Los Angeles, CA): UCLA’s outbreak involved 17 patients: 9 confirmed active infections, 7 asymptomatic carriers, and 1 index patient. Two patients died. Approximately 179 patients were potentially exposed. The pathogen was OXA-232 carbapenem-resistant Klebsiella pneumoniae. The investigation found “no deviations from FDA or manufacturer recommendations” in the hospital’s reprocessing procedures. (Source: Humphries et al., Clinical Infectious Diseases, 2017, PMID 29579235).

What Did Olympus Know About Superbug Transmission Through Scopes?

The evidence of Olympus’s knowledge and its failure to report to the FDA is detailed and documented across federal regulatory records and a criminal conviction. On February 19, 2015, the FDA issued a Safety Communication stating that manufacturer cleaning instructions may be insufficient for all ERCP duodenoscopes, citing 75 medical device reports involving approximately 135 patients between January 2013 and December 2014 (Source: FDA Safety Communication, February 19, 2015).In March 2018, the FDA issued Warning Letter MARCS-CMS 546986 documenting that more than two years after a mandatory postmarket surveillance order, Olympus had established zero surveillance sites. In December 2018, Olympus Medical Systems Corporation pleaded guilty to three counts — and former senior executive Hisao Yabe to one count — of distributing misbranded medical devices. The company paid $85 million in penalties and admitted to failing to file required adverse-event reports with the FDA (Source: DOJ Press Release, December 10, 2018; Case No. 2:18-cr-00727-SRC, U.S. District Court, D.N.J.).In March 2023, the FDA issued Warning Letter MARCS-CMS 654013 documenting that Olympus had failed to investigate cracked MAJ-2315 distal end covers for two years. Most recently, in October 2025, Olympus issued an Urgent Field Safety Notice updating its reprocessing instructions for its current-generation TJF-series duodenoscopes and recommending that 10X magnification tools be used to properly inspect the scopes — tools that hospitals had never previously been told were necessary. The notice confirmed 2 deaths and 5 serious injuries linked to current-generation TJF scopes. The legal argument in this litigation is that Olympus — not the hospital — was responsible for providing safe cleaning instructions. Hospitals reported following the reprocessing instructions provided by Olympus at the relevant time. Whether those instructions were adequate, and whether they were in fact followed in every case, are contested issues that have been examined in litigation and in 2016 Senate HELP Committee findings. Olympus knew those instructions were inadequate and failed to warn hospitals and patients (Source: Olympus Urgent Field Safety Notice, October 2025).

What Qualifying Injuries May Support a Legal Claim?

To evaluate whether you may have a legal claim against Olympus Corporation, you generally must meet the following confirmed criteria:

Notice of exposure? If you received a notice of exposure after an Olympus scope procedure, you may qualify even without a confirmed infection diagnosis — contact us to review your situation.

If the scope or any component broke apart during your procedure and required emergency surgery to remove fragments, this may represent a separate product liability claim — contact us to discuss. Depending on the circumstances of your case and how a potential global resolution is structured, there may still be options worth exploring with an attorney.

What Should I Do If I Developed a Superbug Infection After an Endoscopy?

If you developed an antibiotic-resistant infection following a scope procedure, taking the following steps immediately can protect your legal rights:

1. Preserve your medical records. Request all records from the procedure: the operative or endoscopy report, the scope model number used, and all records from your subsequent hospitalization. Do not wait — hospitals are not required to retain records indefinitely.
2. Request your culture reports. Ask for the laboratory culture report identifying the specific organism and its resistance profile. This is the primary evidence connecting your infection to a contaminated scope. The organism name (e.g., CRE, NDM-1 E. coli, OXA-232 Klebsiella) and the antibiotic resistance panel must be preserved.
3. Note the timing. Record the exact date of your scope procedure and the date your infection symptoms began or your infection was diagnosed. The 30-day window from procedure date is the critical eligibility threshold.
4. Do not contact the hospital about a legal claim without consulting an attorney first. Statements you make to the hospital could affect your case. Speak with an attorney before reaching out.
5. Contact Marin & Murphy. Our attorneys review Olympus scope infection claims for patients in Rhode Island, South Carolina, Connecticut, and Massachusetts, and associate with locally licensed co-counsel to pursue claims nationwide. The consultation is free and creates no obligation.

Marin & Murphy Law Firm is investigating Olympus scope infection claims for patients in Rhode Island, South Carolina, Connecticut, and Massachusetts. Contact us at (888) 348-2735. The consultation is free and creates no obligation.

Matthew T. Marin, J.D. — Admitted in Rhode Island, South Carolina, Connecticut, and Massachusetts

Stefanie A. Murphy, J.D. — Admitted in Rhode Island, Connecticut, and Massachusetts

Qualifying infection types

Carbapenem-Resistant Enterobacteriaceae (CRE) · NDM-1-producing E. coli · ESBL-producing organisms · Klebsiella pneumoniae · Pseudomonas aeruginosa · VRE · MRSA · Sepsis (with hospitalization + IV antibiotics within 30 days) · other multidrug-resistant or healthcare-associated bloodstream infection confirmed by culture

Frequently Asked Questions

Attorney Advertising. Marin & Murphy Law Firm. Prior results do not guarantee a similar outcome.